429 results on '"Michelson, Eric L."'
Search Results
2. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial: Results of the Continuous Electrocardiographic Assessment Substudy
3. Disturbances of Cardiac Rhythm
4. Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium
5. Albuminuria in chronic heart failure: prevalence and prognostic importance
6. Relation of Death Within 90 Days of Non-ST-Elevation Acute Coronary Syndromes to Variability in Electrocardiographic Morphology
7. Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program
8. TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension
9. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved
10. Incidence and Predictors of Hyperkalemia in Patients With Heart Failure: An Analysis of the CHARM Program
11. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure: Data From the CHARM Program and the Duke Databank
12. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
13. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM)--added trial
14. Feasibility of treating prehypertension with an angiotensin-receptor blocker
15. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial
16. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure
17. The evaluation and management of drug effects on cardiac conduction (PR and QRS Intervals) in clinical development
18. Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium
19. Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction
20. Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction: Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program
21. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
22. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
23. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme
24. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme
25. Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
26. Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure
27. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program
28. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity programme
29. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
30. The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program
31. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
32. Predictors of mortality and morbidity in patients with chronic heart failure
33. Evaluation of the Patient with Palpitations and Non-life-threatening Cardiac Arrhythmias
34. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
35. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
36. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
37. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
38. Thrombolytic therapy of acute myocardial infarction: keeping the unfulfilled promises
39. Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the Study of Patients Intolerant of Converting Enzyme inhibitors registry
40. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: A prospective study
41. General Group Discussion: Study Designs: Chronic Patients
42. General Group Discussion: Holter Monitoring
43. Non-Canine Animal Models for Evaluating Antiarrhythmic Efficacy
44. What Animal Models Should Be Used to Define Antiarrhythmic Efficacy? Acute Dog Models
45. Labetalol Hepatotoxicity
46. Effects of encainide and metabolizer phenotype on ventricular conduction during exercise
47. Candesartan Cilexetil: Comparison of once-daily versus twice-daily administration for systemic hypertension
48. Effects of candesartan cilexetil in patients with severe systemic hypertension
49. Calcium Entry Blocking Agents: How to Define Controlled Studies in Patients With Arrhythmias
50. How to Define Beta-Blocker Usefulness in Hypertension, Angina and Arrhythmias: An Overview
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.